← Leaderboards
Yelena Y Janjigian
Sloan-Kettering Inst Can Research
$1,716,445
Attributed
$3,432,890
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $705K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,432,890 · 1
By mechanism
R01$3,432,890 · 1
Top collaborators
- Jason S Lewis5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jason S Lewis$26,024,327
- John Thomas Poirier$4,490,380
- Jan Grimm$17,140,928
- Samuel Singer$8,089,401
- Barry Stephen Taylor$3,136,058
Others in their field
Other Emerging Leaders on “Erbb2 Gene”
- Elizabeth Marjorie Cespedes Feliciano · Columbia University Health Sciences$3,972,532
- Hui-Ming Chang · University Of Missouri-Columbia$3,417,937
- Sarah Marie Cheal · Weill Medical Coll Of Cornell Univ$3,410,761
- Iwei Yeh · University Of California, San Francisco$3,072,504
- Gaorav P. Gupta · Duke University$2,934,385
- Anna C Sorace · University Of Alabama At Birmingham$2,522,448
Research focus
Erbb2 GeneEndocytosisAntibodiesDrug SensitivityCaveolin 1BindingCholesterolBiological MarkersCancer CellClinical ImagingClinical ResearchClinical TranslationClinical TrialsCell MembraneCombined Modality TherapyCopy Number PolymorphismCytotoxic ChemotherapyDisease ProgressionClinical DataDoseDosimetryDrug KineticsDrug ResistanceExhibits
Grant awards (5)
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$695,700
R01 · FY2025 · CA
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$660,915
R01 · FY2024 · CA
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$678,920
R01 · FY2023 · CA
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$692,343
R01 · FY2022 · CA
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$705,012
R01 · FY2021 · CA